Abstract
Purpose Wilms’ tumor 1 (WT1) is overexpressed in several cancers, and WT1 expression levels are associated with poor prognosis. As a host protein that functions as an oncogene, it represents an important immunotherapeutic target. This study evaluated WT1 expression in Kaposi sarcoma (KS) tumors to assess whether immunotherapy targeting WT1 is a potential therapeutic approach for KS. We also investigated the role of the causal agent of KS, Kaposi sarcoma herpesvirus (KSHV/HHV-8) in regulating WT1 expression.
Experimental design Immunohistochemistry for WT1, KSHV, and B and T cells subsets, followed by image analysis, was performed in 363 KS tumor biopsies. Expression of KSHV vFLIP was evaluated by immunofluorescence. Primary endothelial cell cultures and cell lines were infected with KSHV in vitro, or transduced with an inducible vFLIP vector and induced with doxycycline, and then assessed for WT1 expression. Binding of ESK-1, a T cell receptor mimic therapeutic antibody that recognizes WT1 peptides presented on MHC HLA-A0201, was assessed using flow cytometry.
Results We report overexpression of WT1 in KS tumors, which was associated with increased with increasing histopathologic stage and the proportion of KSHV-infected cells. Areas with high WT1 expression showed sparse T cell infiltrates. KSHV infection in vitro resulted in WT1 upregulation, mediated by the viral protein vFLIP, which resulted in stronger binding of ESK1.
Conclusions KS lesions express high levels of WT1, a process regulated by the KSHV-encoded vFLIP. These findings suggest that immunotherapy directed against WT1 may represent a therapeutic approach for this cancer.
Translational Relevance Kaposi sarcoma (KS) is a vascular neoplasm caused by the Kaposi sarcoma herpesvirus (KSHV/HHV-8). People living with HIV are not only at a significantly higher risk of developing KS, but also often have a more aggressive clinical course. Although antiretroviral therapy may cause regression of HIV-associated KS lesions, advanced cases of KS also require chemotherapy, which is rarely curative. Wilms’ tumor 1 (WT1) has been reported to be overexpressed in various cancers, functioning as an oncogene and associated with a poor prognosis. WT1 is also an important immunotherapeutic target, with several WT1-directed therapies showing promising results in early clinical trials for leukemias and solid tumors. Here we report high expression of WT1 in KS, especially in higher histological stages. Our findings provide pre-clinical evidence that supports conducting anti-WT1 immunotherapy trials in KS, and evaluating WT1 expression as a potential biomarker to identify individuals most likely to benefit.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; DAS is a consultant to, or has equity in, or is on the Board of: Sellas, Eureka, Oncopep, Pfizer, Repretoire, CoImmune, Iovance; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This investigation was supported by grant KL2TR002385 of the Clinical and Translation Science Center at Weill Cornell Medical College and NIH R01 R01CA CA250074 to EC. Clinical trial AMC066/A5263 was supported by AMC grant U01 CA121947 from the National Cancer Institute and the ACTG awards UM1 AI068634, UM1 AI068636, and UM1 AI106701 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank Dr. Ashlee V. Moses at Oregon Health and Science University for generously providing the recombinant KSHV BAC16 constructs. We thank Dr. Michael Sturzl from University of Erlangen-Nuremberg, Germany for providing the KSHV vFLIP rat monoclonal antibody. We thank Dr. Annamalai Selvakumar, PhD, and Dr. Richard O'Reilly for providing the HLA-A0201 plasmid vector. We thank Jouliana Sadek and other members of the Weill Cornell Medicine-Cesarman laboratory for critical discussion and feedback. Project support for this research was provided in part by the Center for Translational Pathology at the Department of Pathology and Laboratory Medicine, Weill Cornell Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The immunophenotyping of all human KS specimens was reviewed and approved by the Institutional Review Board (IRB) of Weill Cornell Medicine, whether they were obtained from the Department of Pathology of Weill Cornell Medicine/New York Presbyterian Hospital, or received from our collaborators. In addition, a subset of cases from Chicago were also approved for this use by the Cook County Health Office of Research and Regulatory Affairs (IRB). The separate cohort from Uganda was approved by the Makerere University School of Biomedical Sciences Ethics Review Committee. Lastly, cases from clinical trial A5264/AMC066 were from 11 AIDS Clinical Trials Group (ACTG) sites in Brazil, Kenya, Malawi, South Africa, Uganda, and Zimbabwe, all of which obtained approval from local and national ethics committees (Lancet. 2020 Apr 11;395(10231):1195-1207)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available within the article or its supplementary materials.
